Review of NICE Technology Appraisal Guidance No. 228; Bortezomib and thalidomide for the first-line treatment of multiple myeloma

Proposal to incorporate the guidance into a Clinical Guideline

The planned date for review of the above guidance was July 2014.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full appraisal review.

The recommendations made in TA228 were informed by the VISTA and MMIX trials. Updated results from both trials have since been published, but they reinforce the clinical effectiveness data in TA228 and would not lead to a change in the existing recommendations.

There is a clinical guideline in development for the diagnosis and management of myeloma, which is due to be published in January 2016. 

As a result, we believe that it would be appropriate to move TA228 to the technology appraisal static list and for the recommendations to be incorporated into the forthcoming clinical guideline. This has the consequence of preserving the funding direction.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.  Please see appendix A for a full list of the organisations we have contacted. 

January 2015

Attachments